Inspur Information Releases 2020 Global Computing Index Report
26.2.2021 11:07:00 EET | Business Wire | Press release
Inspur Information, a leading IT infrastructure solutions provider, has sponsored an International Data Corporation (IDC) white paper on the 2020 Global Computing Index (henceforth referred to as The Report). As the world’s first index report on computing, The Report unveils the relationship between computing power and economic development and serves as a reference for the outlook of the global digital economy.
Global digital transformation has entered a phase marked by exponential growth in innovation, with the size of the digital economy projected to continue on an upward trend. As a key factor that underlies digital technology development, computing is now defining the productivity of the digital economy era. According to The Report, economic growth directly correlates with the development of computing—one point of growth in the computing index translates to a 3.3‰ rise in the size of the digital economy and a 1.8‰ growth in GDP. Specifically, AI computing market share is projected to continue on this upward trajectory. Research on computing markets in sample countries shows that AI computing market share has grown from 7% in 2015 to 12% of the overall computing market in 2019 and is expected to reach 23% in 2024. With the largest number of hyper-scale data centers in the world, the United States has demonstrated its strong infrastructure support for computing power growth, ranking first on the index ranking with a score of 75. In second place with a score of 66 is China, followed by Japan (55), Germany (52), and the United Kingdom (47).
The Global Computing Index represents a year-long joint effort by Inspur Information and IDC. The Report, covering Australia, Brazil, China, France, Germany, Japan, Russia, South Africa, the United Kingdom, and the United States, offers a comprehensive assessment of computing power across four dimensions: computing capacity, computing efficiency, application level, and infrastructure support.
Zhang Dong, vice president of Inspur Information, noted that "the application of emerging technologies, especially AI, will be driving the advancement of computing. As the volume of data and the complexity of algorithms continues to rise, computing will be the determining factor for the AI development ceiling.”
Computing Defines Productivity in the Digital Economy Era; Synchronized Development of Emerging Technology Applications and Computing will Foster Economic Growth
The development of emerging technologies and computing are mutually beneficial in that computing power provides infrastructure support for emerging technologies, which in turn pushes forward the evolution of computing. IoT, AI, and big data are among the major emerging technologies.
In 2020, the global spending on AI by enterprises was forecast to be US$49.87 billion, and this number is estimated to reach US$96.28 billion by 2023. The development of AI is driven by the advancement in computing, data, and algorithms, and sufficient computing power is necessary for the processing of large amounts of data using complex algorithms. The widespread application of IoT will give rise to the fast advancement of edge computing, which has already reshaped IT infrastructure and will revolutionize computing, storage, and networks. Cloud computing is the most important means for improving computing efficiency. IT infrastructure that supports same-pace development of cloud and edge will enable applications of emerging technologies, improve computing power, and eventually reap bigger economic rewards. AI, IoT, cloud computing, and other emerging technologies will be the main drivers for IT spending in the future.
Inspur Empowers Computing Power Upgrade through Investment in Open Computing and Artificial Intelligence
The Report builds a comparative formula between computing power and economic development and serves as a reference for countries to improve their computing power and economic competitiveness. The digital economy is a significant component of GDP and computing is the foundation for the development of the digital economy.
As a leading force in emerging technologies, Inspur is the only server vendor who has joined all major open computing organizations, including OCP (Open Compute Project), ODCC and Open19, and is a Gold Member of OpenStack. Inspur leads the OpenRMC subproject, which focuses on next-generation data center management standards, and is an active member in OAM specification, the Scorpio Project, and the OTII for establishing edge computing standards.
In artificial intelligence, Inspur is the chair of SPEC ML, the Technical Committee on Machine Learning under the international evaluation organization SPEC. While working closely with leading tech companies in AI systems and applications, Inspur leads SPEC ML in the development of AI Test specifications and related benchmarks. As of today, Inspur has the most complete array of GPU servers in the industry with nearly 20 computing platforms supporting GPU numbers ranging from 4 to 64. Inspur also provides ultimate-design GPU servers such as the Inspur NF 5488A5, a 19-time record-setting server in the MLPerf benchmarks. Inspur currently offers full-stack AI capabilities including AI Computing Platform, AI Resource Suite, and Algorithm Toolkit.
Please click for more insights from the report.
About Inspur Information
Inspur Electronic Information Industry Co., LTD is a leading provider of data center infrastructure, cloud computing, and AI solutions, ranking among the world’s top 3 server manufacturers. Through engineering and innovation, Inspur delivers cutting-edge computing hardware design and extensive product offerings to address important technology arenas like open computing, cloud data center, AI and deep learning. Performance-optimized and purpose-built, our world-class solutions empower customers to tackle specific workloads and real-world challenges. To learn more, please go to en.inspur.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005020/en/
Contact information
Fiona Liu
Inspur Information
liuxuan01@inspur.com
Vivian Dadamio
vivian@allisonpr.com
+49 89 3888 920 10
+49 (0)176 32 666 550
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
